For a Division that started in 2010, today KRIS commands the highest growth with a progressive trend. Focus on segments such as anti-infective, gastro-intestinal, anti-allergic, anti-viral, dermatological, analgesic & anti-inflammatory, rejuvenator, and lifestyle drugs, the Division has raced ahead, with its business growing three-fold between 2010-2015, and now, with revenues of Rs 100 Crore.
The story goes that it was decided to venture into the fastest growing segments in the pharmaceutical industry and to reach out to a whole lot of General Physicians and Consultants. KRIS, from the very beginning, has focused on the high-margin therapy products that have made the Division grow profitable.
In almost every instance, the Division has managed to diversify into new areas. When it recently opened its operations in Assam and Tamil Nadu it gained entry into an unexplored space; with KRIS it was able to gain new foot-holds. The story is much the same with its latest new launches in the nutraceutical and cough segment.
When KRIS first started selling its products on a National scale, way back in 2010, it ranked low on the list. Today, with a domestic market share of 1.01 percent in its represented market, it is ranked number twenty-fourth. The numbers tell the story; whether it's building a profitable business or creating wealth, a good job done!
Copyright © 2024 All Rights Reserved by Hetero Healthcare Limited.